38 results
8-K
EX-99.2
DAWN
Day One Biopharmaceuticals Inc
18 Jun 24
Entry into a Material Definitive Agreement
8:36am
Months Ended Three Months Ended $ Millions 3/31/24 3/31/23 R&D Expense $40.2 $27.8 G&A Expense $26.6 $18.0 Net Loss $62.4 $42.4 FIREFLY-1: Pivotal Phase
8-K
EX-99.1
DAWN
Day One Biopharmaceuticals Inc
12 Jun 24
Regulation FD Disclosure
8:07am
: $317.9 million (no debt) in gross proceeds outstanding as of May 1, 2024 Three Months Ended Three Months Ended $ Millions 3/31/24 3/31/23 R&D Expense
8-K
EX-99.2
DAWN
Day One Biopharmaceuticals Inc
30 May 24
Day One Announces Sale of Priority Review Voucher for $108 Million
8:35am
: $317.9 million (no debt) in gross proceeds outstanding as of May 1, 2024 Three Months Ended Three Months Ended $ Millions 3/31/24 3/31/23 R&D Expense $40.2
8-K
EX-99.1
DAWN
Day One Biopharmaceuticals Inc
6 May 24
Day One Reports First Quarter 2024 Financial Results and Corporate Progress
4:30pm
, management believes it has sufficient capital resources to fund anticipated operations into 2026.
R&D Expenses: Research and development expenses were $40.2
8-K
EX-99.2
DAWN
Day One Biopharmaceuticals Inc
6 May 24
Day One Reports First Quarter 2024 Financial Results and Corporate Progress
4:30pm
Months Ended3/31/24 Three Months Ended3/31/23 R&D Expense $40.2 $27.8 G&A Expense $26.6 $18.0 Net Loss $62.4 $42.4 Cash, cash equivalents and short
8-K
EX-99.2
96ydcdy r9x4kr
24 Apr 24
Regulation FD Disclosure
8:01am
8-K
EX-99.2
yreg6r9byme
26 Feb 24
Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress
4:30pm
8-K
EX-99.1
2lg200sjdpnqi41 d5kj
26 Feb 24
Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress
4:30pm
8-K
EX-99.2
9ehc4932bi52pd
8 Jan 24
Regulation FD Disclosure
8:30am
8-K
EX-99.2
pys1cojf034o54lamlkh
17 Nov 23
Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine
7:07am
8-K
EX-99.2
ms4ieizx6j2q1f
6 Nov 23
Day One Reports Third Quarter 2023 Financial Results and Corporate Progress
4:30pm
8-K
EX-99.1
10o8rrwlknril
6 Nov 23
Day One Reports Third Quarter 2023 Financial Results and Corporate Progress
4:30pm
8-K
EX-99.2
mwc4ug
30 Oct 23
Regulation FD Disclosure
8:12am
8-K
EX-99.2
50fnp16m
11 Sep 23
Regulation FD Disclosure
8:35am
8-K
EX-99.2
sfvdjlfa67u 66r
16 Aug 23
Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience
8:06am
8-K
EX-99.1
yu6a0ou
7 Aug 23
Day One Reports Second Quarter 2023 Financial Results and Corporate Progress
4:30pm
8-K
EX-99.2
ccrdhyjf7ycp hc76
7 Aug 23
Day One Reports Second Quarter 2023 Financial Results and Corporate Progress
4:30pm
8-K
EX-99.1
h7vh8 239mj
12 Jun 23
Regulation FD Disclosure
8:07am
8-K
EX-99.1
bbd8ctj
5 Jun 23
Regulation FD Disclosure
6:08am